HKSE - Delayed Quote HKD

Shanghai Henlius Biotech, Inc. (2696.HK)

35.250

-0.250

(-0.70%)

At close: May 9 at 4:08:05 PM GMT+8

Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

On April 29, 2025, Shanghai Henlius Biotech, Inc. (2696.HK) announced a licensing agreement with Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, granting exclusive commercialization rights for its self-developed ipilimumab biosimilar HLX13 in the United States, 42 European countries and regions, Japan, Canada, and Australia.

PR Newswire 12 days ago

2696.HK
-0.70%
Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights

Henlius (2696.HK) held its 2025 Global R&D Day themed "Collaborate to Create," gathering senior executives, experts, and industry leaders to discuss R&D advances, strategic planning, and cutting-edge therapies. The event attracted hundreds from academia, industry, and investment sectors.

PR Newswire 24 days ago

2696.HK
-0.70%
Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report

On April 15, 2025, Henlius (2696.HK) released the "2024 Environmental, Social, and Governance (ESG) Report" (hereinafter referred to as the "ESG Report" or "Report"). This marks the sixth consecutive year that the company has submitted an ESG-related report to global stakeholders, comprehensively showcasing Henlius' remarkable achievements and steadfast commitment across 5 key ESG pillars: Product, Talent, Environment, Society, and Corporate Governance.

PR Newswire 25 days ago

2696.HK
-0.70%
Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug

Organon (OGN) and Shanghai Henlius Biotech said Friday the European Medicines Agency has validated t

PREMIUM
MT Newswires last month

^YH206
Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY

Henlius (2696.HK) announced its 2024 annual results. During the reporting period, Henlius' total revenue reached approximately RMB5.7244 billion, representing an increase of 6.1% YoY. The net profit reached RMB820.5 million, a 50.3% YoY growth, with a net profit margin of 14.3%, up by 41.6% YoY. This marks Henlius' second consecutive year of full-year profitability following its first profitable year in 2023. The increasing commercial sales of core products have been a key driver of profitabilit

PR Newswire last month

2696.HK
-0.70%
Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal antibody (mAb) for the treatment of gastric cancer.

PR Newswire last month

2696.HK
-0.70%
Dr Reddy’s and Shanghai Henlius sign agreement for HLX15

Henlius could earn up to $131.6m, including an upfront payment of $33m.

Pharmaceutical Technology 3 months ago

^YH206

RDY
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

HYDERABAD, India, February 06, 2025--Dr. Reddy’s Laboratories SA today announced that it has entered into a license agreement with Henlius related to the commercialization of HLX15.

Business Wire 3 months ago

2696.HK
-0.70%

RDY
Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as "Dr. Reddy's") for the company's independently developed investigational daratumumab biosimilar HLX15, a recombinant anti-CD38 fully human monoclonal antibody injection. Dr. Reddy's will gain exclus

PR Newswire 3 months ago

RDY

2696.HK
-0.70%
Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Shanghai Henlius Biotech, Inc. (2696.HK) announced that its anti-PD-1 mAb, HANSIZHUANG (serplulimab, marketed as Hetronifly® in Europe), has been officially approved by the European Commission (EC) for use in combination with carboplatin and etoposide as a first-line treatment of adult patients with ES-SCLC. This approval establishes serplulimab as the first and only anti-PD-1 mAb approved in the EU for the treatment of ES-SCLC.

PR Newswire 3 months ago

2696.HK
-0.70%
Palleon and Shanghai Henlius Biotech link on autoimmune therapy

Henlius has secured an exclusive licence to develop and commercialise E-602 in China.

Pharmaceutical Technology 4 months ago

^YH206
High Growth Tech Stocks Including Shanghai Henlius Biotech

As global markets experience fluctuations with major indexes like the Nasdaq Composite reaching new highs, small-cap stocks face challenges as evidenced by the Russell 2000's recent underperformance. Amidst these dynamics, high growth tech stocks such as Shanghai Henlius Biotech stand out by leveraging innovation and adaptability to navigate economic shifts and investor expectations.

Simply Wall St. 4 months ago

2432.TW

2696.HK
-0.70%
First Shipment of Henlius Trastuzumab to U.S.

On November 29, 2024, Henlius' independently developed and produced trastuzumab biosimilar, HANQUYOU (trade name: HERCESSI™ in the U.S. and Zercepac® in Europe), departed from Henlius' Songjiang First Plant, heading to the U.S. This milestone marks the company's first commercial supply to North America, representing a significant breakthrough in its global expansion. With this achievement, Henlius has successfully extended its commercial supply network to include China, Europe, Latin America, th

PR Newswire 5 months ago

2696.HK
-0.70%
Henlius and SVAX Forge Strategic Partnership in the MENAT Market

On the morning of November 7, at the 7th China International Import Expo (CIIE), Henlius (2696.HK) entered into a strategic collaboration with AL-TIRYAQ AL-KHALAWI Medical Company ("SVAX"), a subsidiary entity of Saudi Arabia's prominent family business group in the healthcare sector, the Fakeeh Family. The two parties will establish joint ventures in Saudi Arabia to integrate Henlius' leading capabilities in the research, development, and manufacturing of biologics with SVAX's local expertise i

PR Newswire 5 months ago

2696.HK
-0.70%
Henlius, XtalPi sign deals to expand abroad as Chinese drug companies 'go out' for growth

Two Chinese technology firms involved in the development of pharmaceutical drugs have clinched partnership agreements in Southeast Asia and the Middle East, as the industry increasingly looks beyond China's shores with its cutting edge technology in search of growth opportunities. Fosun Group's Shanghai Henlius Biotech subsidiary struck a deal with the Fakeeh family's Al Tiryaq Al-Khalawi Medical Company (SVAX) to set up two ventures in Saudi Arabia to produce and market pharmaceuticals, accordi

South China Morning Post 5 months ago

^YH103

^YH206
High Growth Tech Stocks To Explore In November 2024

As global markets navigate a complex landscape marked by cautious earnings reports and mixed economic signals, the technology sector remains a focal point, with small-cap stocks demonstrating resilience amid broader market fluctuations. In this environment, investors often look for tech stocks that exhibit strong fundamentals and innovative potential to weather volatility and capitalize on growth opportunities.

Simply Wall St. 6 months ago

2696.HK
-0.70%
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

SHANGHAI, China & JERSEY CITY, N.J., October 30, 2024--Henlius and Organon announced US FDA has accepted the Biologics License Application (BLA) for HLX14, biosimilar candidate of PROLIA/XGEVA (denosumab).

Business Wire 6 months ago

2696.HK
-0.70%

OGN
Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending approval of HANSIZHUANG (serplulimab), Henlius' independently developed anti-PD-1 monoclonal antibody (mAb), as a first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). In 2023, Henlius entered into an exclusive license agreement with Intas Pharmaceuticals Limited ("Intas") for the develo

PR Newswire 7 months ago

2696.HK
-0.70%
High Growth Tech Stocks In Hong Kong To Watch

The Hong Kong market has seen notable activity recently, with the Hang Seng Index advancing amidst a backdrop of cautious global sentiment and light economic calendars. This environment sets the stage for examining high-growth tech stocks that could potentially thrive under these conditions. In this article, we will explore three promising tech stocks in Hong Kong, focusing on their potential to capitalize on current market dynamics and economic indicators.

Simply Wall St. 8 months ago

KSHTY

KUASF

LNVGF

Performance Overview

Return	2696.HK	HANG SENG INDEX (^HSI)
YTD	+48.73%	+14.00%
1-Year	+107.84%	+23.36%
3-Year	+123.10%	+14.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Shanghai Henlius Biotech, Inc. (2696.HK)

Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

Henlius 2025 Global R&D Day: Harnessing the Power of Innovation to Propel Global Strategy to New Heights

Putting Patients First, Co-Creating a Bright Future for Human Health: Henlius Releases 2024 ESG Report

Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug

Henlius 2024 Annual Results: Steady Revenue Growth with a Net Profit of RMB820.5 million, Up by 50.3% YoY

Henlius Receives Orphan Drug Designation for Innovative Anti-HER2 mAb HLX22 in the U.S. for Gastric Cancer

Dr Reddy’s and Shanghai Henlius sign agreement for HLX15

Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and Europe

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Palleon and Shanghai Henlius Biotech link on autoimmune therapy

High Growth Tech Stocks Including Shanghai Henlius Biotech

First Shipment of Henlius Trastuzumab to U.S.

Henlius and SVAX Forge Strategic Partnership in the MENAT Market

Henlius, XtalPi sign deals to expand abroad as Chinese drug companies 'go out' for growth

High Growth Tech Stocks To Explore In November 2024

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Henlius Receives Positive CHMP Opinion for HANSIZHUANG as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer

High Growth Tech Stocks In Hong Kong To Watch

Performance Overview